Figure 5.

CRISPR/Cas9 treatment leads to a greater degree of cell cycle arrest than TALEN treatment. (A) Schematic of H11 L2 and R2 TALEN plasmids encoding NLS-mClover3. (B) Schematic of experimental design of ara-C-based cell cycle arrest assay. (C) Dot plot of ratios of Clover+ cells after 5 days of ara-C treatment versus vehicle for indicated cell lines and transfected vectors. n = three independent experiments each consisting of two ara-C-treated technical replicates and one vehicle-treated control. Error bars indicate SEM. *P < 0.05, ***P < 0.0005. Data were analyzed with a one-sample t-test comparing the actual mean against a theoretical mean of 1.